Sumitomo Pharma America, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03292016
- Locations
- ๐บ๐ธ
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
๐บ๐ธParkinson's Disese Treatment Center of SW Florida, Port Charlotte, Florida, United States
๐บ๐ธQUEST Research Institute, Farmington Hills, Michigan, United States
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT03231800
- Locations
- ๐บ๐ธ
Avida Inc, Newport Beach, California, United States
๐บ๐ธQps-Mra, Llc, South Miami, Florida, United States
๐บ๐ธSouth Shore Psychiatric Services PC, Hingham, Massachusetts, United States
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- Conditions
- Parkinson's DiseaseOff Episodes of Parkinson Disease
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03187301
- Locations
- ๐บ๐ธ
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
๐บ๐ธThe Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
๐บ๐ธAtlanta Center for Medical Research, Atlanta, Georgia, United States
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT03149003
- Locations
- ๐บ๐ธ
Piedmont brain tumor center, Atlanta, Georgia, United States
๐บ๐ธCedars Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธHighlands Oncology Group, Fayetteville, Arkansas, United States
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
- Conditions
- Epilepsy With Partial On-set Seizures
- Interventions
- First Posted Date
- 2017-04-17
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT03116828
- Locations
- ๐บ๐ธ
Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States
๐บ๐ธAston Ambulatory Care Center, Dallas, Texas, United States
๐บ๐ธNorthwestern Medical Group, Deparment of Neurology, Chicago, Illinois, United States
A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Registration Number
- NCT03108729
- Locations
- ๐บ๐ธ
Child Neurology Specialists / Clinical Research Center of Nevada, LLC, Henderson, Nevada, United States
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
- Conditions
- Binge Eating Disorder
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 491
- Registration Number
- NCT03107026
- Locations
- ๐บ๐ธ
Lytle and Weiss PLLC, Denver, Colorado, United States
๐บ๐ธClinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
๐บ๐ธBioscience Research, LLC, Mount Kisco, New York, United States
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1134
- Registration Number
- NCT02993731
- Locations
- ๐บ๐ธ
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
๐บ๐ธWinship Cancer Institute of Emory University, Atlanta, Georgia, United States
๐บ๐ธMontefiore Cancer Center, Bronx, New York, United States
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02826161
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)Binge-Eating Disorder Disorder
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02795637
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
๐บ๐ธDaVita Clinical Research, Minneapolis, Minnesota, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States